Back to Search
Start Over
EGFR-mutated advanced lung cancer. Data from a single institution, the Hospital of Leon, in Spain.
- Source :
- Journal of Oncology Pharmacy Practice; Jun2023, Vol. 29 Issue 4, p854-860, 7p
- Publication Year :
- 2023
-
Abstract
- Introduction: 10–16% of non-small cell lung cancer (NSCLC) cases have the epidermal growth factor receptor (EGFR) amplified and/or mutated. Studies show that EGFR tyrosine kinase inhibitors (TKIs) significantly prolong progression-free survival (PFS) in patients with advanced NSCLC compared to those treated with platinum-based chemotherapy (CT) doublets. Our aim is to perform a real-world survival analysis of patients treated with TKI as first-line therapy at the Hospital of Leon (CAULE) in Spain. The impact on global survival rates and responses to clinical and histopathological factors were also analyzed. Material and methods: We retrospectively reviewed patients diagnosed with EGFR-mutated NSCLC who received treatment with EGFR-TKI in the Department of Oncology at the University of Leon Health Center complex between March 2011 and June 2018. Data was analyzed with Kaplan-Meier and Cox regression models to show overall survival (OS), progression-free survival (PFS), and the associated variables. Results: 53 patients were included in the study, 50% (n = 27) were treated with gefitinib, 32% (n = 18) with erlotinib and 10% (n = 6) with afatinib. The median OS and PFS were 27.7 months (95% CI: 21–33.8 months) and 18 months (95% CI 14.25–21.89 months), respectively. The variables associated with OS and with PFS were exon19 deletion as a protective factor and presence of extrathoracic metastasis as a risk factor. The most frequent adverse effects were rash, diarrhea, asthenia, and conjunctivitis. Conclusions: Real-world analysis of this data confirms that treatment with TKI is beneficial for patients diagnosed with EGFR-mutated NSCLC. Our OS outcomes were similar to those reported in clinical trials. [ABSTRACT FROM AUTHOR]
- Subjects :
- HOSPITALS
GENETIC mutation
CONFIDENCE intervals
EPIDERMAL growth factor receptors
LUNG tumors
RETROSPECTIVE studies
ERLOTINIB
METASTASIS
PROTEIN-tyrosine kinase inhibitors
GEFITINIB
AFATINIB
SURVIVAL analysis (Biometry)
KAPLAN-Meier estimator
DESCRIPTIVE statistics
HISTOLOGY
PROGRESSION-free survival
DRUG side effects
PROPORTIONAL hazards models
Subjects
Details
- Language :
- English
- ISSN :
- 10781552
- Volume :
- 29
- Issue :
- 4
- Database :
- Complementary Index
- Journal :
- Journal of Oncology Pharmacy Practice
- Publication Type :
- Academic Journal
- Accession number :
- 164375293
- Full Text :
- https://doi.org/10.1177/10781552221085253